Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration |
| gptkbp:ATCCode |
D11AH07
|
| gptkbp:brand |
gptkb:Adtralza
Adbry |
| gptkbp:CASNumber |
872365-14-5
|
| gptkbp:developer |
gptkb:LEO_Pharma
|
| https://www.w3.org/2000/01/rdf-schema#label |
tralokinumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
IgG4 monoclonal antibody
|
| gptkbp:mechanismOfAction |
blocks IL-13 signaling
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
injection site reaction
conjunctivitis upper respiratory tract infection |
| gptkbp:target |
gptkb:interleukin-13
|
| gptkbp:usedFor |
gptkb:atopic_dermatitis
|
| gptkbp:bfsParent |
gptkb:IL-13
gptkb:Interleukin_13 gptkb:interleukin-13 gptkb:interleukin-13_protein |
| gptkbp:bfsLayer |
7
|